ArticleCureus2025
Angiotensin-Converting Enzyme Inhibitor (ACEI)-Induced Angioedema After Re-exposure to Lisinopril: A Case Report and Clinical Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema is an uncommon but potentially life-threatening adverse effect that can occur unpredictably, even after prolonged use. Prompt recognition and appropriate management are essential. We present the case of a 54-year-old Caucasian male with a history of ACEI-induced angioedema who developed isolated lingual swelling after re-exposure to lisinopril. His symptoms were unresponsive to antihistamines, corticosteroids, and epinephrine but resolved with supportive care following ACEI discontinuation. This case underscores the risk of recurrent angioedema following ACEI re-exposure and reinforces the recommendation for lifelong avoidance of ACEIs in patients with a prior diagnosis of ACEI-induced angioedema. Angiotensin receptor blockers (ARBs), which carry a lower risk of angioedema, may serve as preferred alternatives in high-risk patients. Patient education remains critical to preventing recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.